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Abstract: In a subgroup of patients with systemic sclerosis (SSc), vasospasm affecting the pulmonary circulation may contribute to worsening
respiratory symptoms, including dyspnea. Noninvasive assessment of pulmonary blood ﬂow (PBF), utilizing inert-gas rebreathing (IGR) and
dual-energy computed-tomography pulmonary angiography (DE-CTPA), may be useful for identifying pulmonary vasospasm. Thirty-one
participants (22 SSc patients and 9 healthy volunteers) underwent PBF assessment with IGR and DE-CTPA at baseline and after provocation
with a cold-air inhalation challenge (CACh). Before the study investigations, participants were assigned to subgroups: group A included SSc
patients who reported increased breathlessness after exposure to cold air (n = 11), group B included SSc patients without cold-air sensitivity
(n = 11), and group C patients included the healthy volunteers. Median change in PBF from baseline was compared between groups A, B, and
C after CACh. Compared with groups B and C, in group A there was a signiﬁcant decline in median PBF from baseline at 10 minutes (−10%;
range: −52.2% to 4.0%; P < 0.01), 20 minutes (−17.4%; −27.9% to 0.0%; P < 0.01), and 30 minutes (−8.5%; −34.4% to 2.0%; P < 0.01) after
CACh. There was no signiﬁcant difference in median PBF change between groups B or C at any time point and no change in pulmonary
perfusion on DE-CTPA. Reduction in pulmonary blood ﬂow following CACh suggests that pulmonary vasospasm may be present in a sub-
group of patients with SSc and may contribute to worsening dyspnea on exposure to cold.
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Raynaud’s phenomenon (RP), characterized by triphasic color changes
secondary to digital artery vasospasm and subsequent reperfusion, is
present in more than 90% of patients with systemic sclerosis (SSc)
and is a cardinal feature of the disease.1 Debate continues as to the
presence and clinical signiﬁcance of a more widespread visceral vaso-
spastic process in SSc, with evidence of cold-induced ischemia affect-
ing the myocardium,2-5 brain,6-9 and kidneys.10 Vasospasm affecting
the pulmonary circulation remains controversial but may be of partic-
ular importance, given the high prevalence of pulmonary hyperten-
sion in SSc.11 Similar histological changes have been reported in the
digital arteries and pulmonary arteries,12 and it is possible that repeti-
tive pulmonary vasospasm may be one mechanism contributing to
eventual ﬁxed pulmonary hypertension in SSc.13
Various measurement techniques (including right heart catheteri-
zation [RHC], radioisotope lung perfusion scans, and diffusing ca-
pacity of the lung for carbon monoxide [DLCO]) have been evaluated
for the detection of pulmonary vasospasm, with varying results.14-22
Technological advances now allow for the assessment of pulmonary
blood ﬂow (PBF) with several noninvasive techniques, including inert-
gas rebreathing (IGR) and dual-energy computed-tomography pul-
monary angiography (DE-CTPA).
Measurement of PBF with IGR is well established and has been
validated against cardiac catheterization and cardiac magnetic reso-
nance imaging (MRI).23-25 Gas concentration analysis performed
with photoacoustic spectroanalysis enables rapid, accurate, and re-
producible PBF measurements26 and provides a measure of whole-
lung, or “global,” pulmonary perfusion. DE-CTPA, an evolving im-
aging modality, allows simultaneous image acquisition at the same
phase of contrast enhancement, enabling the creation of an “iodine
map” of pulmonary perfusion.27 In contrast with IGR-measured
global PBF, postprocessing DE-CTPA techniques allow the analysis
of regional lung perfusion differences. We hypothesized that pulmo-
nary vasospasm in SSc patients could be provoked with an inhala-
tional cold-air challenge and may be detectable as a change in global
or regional pulmonary perfusion from baseline measurements, as
measured by IGR and DE-CTPA.
METHODS
Patient selection
Twenty-two patients with SSc attending the Royal Brompton Hospi-
tal Interstitial Lung Disease Clinic were evaluated prospectively be-
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tween January 2011 and October 2012. Nine healthy volunteers were
recruited as control subjects. All patients met the American College
of Rheumatology criteria for SSc,28 and only patients with limited in-
terstitial lung involvement (deﬁned as interstitial lung disease [ILD]
extent of <20% on high-resolution computed tomography [CT] and/
or forced vital capacity [FVC] of >70%)29 were recruited to the study
(to minimize the risk of interstitial change confounding DE-CTPA
interpretation). No patient had pulmonary hypertension, and all pa-
tients had undergone screening echocardiography in the previous
12 months. No patients were receiving pulmonary vasodilator ther-
apy (endothelin receptor antagonists, phosphodiesterase 5 inhibitors,
or prostacyclins) or calcium channel antagonists.
Before undertaking the study protocol, patients were classiﬁed
into three groups. Group A consisted of SSc patients who reported
new or worsening dyspnea during cold exposure (suggestive of pul-
monary vasospasm), group B of patients with SSc in whom dys-
pnea did not change on exposure to cold, and group C of healthy
volunteers. Local ethics committee approval was given for the
study, and informed consent was obtained from all participants.
Statistical analysis
All analyses were performed with STATA statistical software (ver.
12.0; Stata, College Station, TX). Data were expressed as mean and
standard deviation (SD) or as median and range, as appropriate.
Comparisons of PBF measurements (percent change from base-
line) were made with the Wilcoxon signed-rank test. Spearman’s
rank correlation was calculated, comparing change in DE-CTPA
parameters (including mean lung attenuation [MLA] and pixel
intensity, as described in “DE-CTPA image analysis” below) with
changes in PBF.
Study protocol
The sequence of study investigations is outlined in Figure 1, and all
participants completed the study investigations in a single visit. Base-
line spirometry and PBF measurements were performed, followed by
a modiﬁed 3-minute isocapneic hyperventilation cold-air challenge
(CACh; described below). After completion of the CACh, repeat spi-
rometry was performed, followed by serial PBF measurements every
5–10 minutes for 30 minutes. After completion of respiratory ma-
neuvers, a minimum 2-hour “rest break” was enforced. Following
the break, baseline DE-CTPA was performed, followed by a second
CACh. Repeat DE-CTPA was performed, timed to coincide with the
maximum observed post-CACh change in PBF. If no post-CACh
change in PBF was observed, the DE-CTPA was performed 10–
20 minutes after CACh. The exact timing of the DE-CTPA was re-
corded, and all parameters between examinations for each patient
were kept constant. Individual study investigations are described
in detail below.
Spirometry. Forced expiratory volume in 1 second (FEV1) and
FVC were measured (Jaeger Masterscreen; Cardinal Health UK 240,
Warwick, UK) at baseline and after cold-air inhalation, to assess for
cold-induced bronchoconstriction.
CACh. A modiﬁed isocapneic hyperventilation CACh (based on
the protocol to assess for exercise-induced bronchoconstriction)30,31
was undertaken as the provoking stimulus with which to induce
pulmonary vasospasm. Three minutes of isocapneic hyperventilation
at rest was performed at 60% of maximum voluntary ventilation
(with a gas mixture of 5% CO2, 21% O2, and 73% nitrogen) with the
TurboAire Challenger device (VacuMed, Ventura, CA). This porta-
ble handheld device utilizes a series of geometrically arranged in-
ternal “ﬁns” to alter airﬂow kinetic energy and achieve rapid air
cooling. As measured by a temperature probe at the mouthpiece,
inhaled-air temperature was maintained at −10° to −15°C.
PBF measurement. PBF measurement using IGR was per-
formed with the Innocor device (Innovision, Odense, Denmark).
IGR (based on the Fick principle) involves the inhalation of a gas
mixture containing a soluble and an insoluble gas, with PBF propor-
tional to the rate of decline of the soluble compound.23,24 With in-
line photoacoustic gas analysis, concentrations of nitrous oxide
(N2O; blood soluble) and sulphur hexaﬂuoride (SF6; blood insoluble)
can be rapidly measured, with PBF proportional to the rate of de-
cline of N2O as it is cleared by the pulmonary circulation. PBF
measurements were performed at baseline (PBFpre-CACh) and serially
(every 5–10 minutes) after CACh.
DE-CTPA. Dual-energy CT enables simultaneous acquisition of
data at differing x-ray tube voltages, and with contrast enhancement,
DE-CTPA allows evaluation of pulmonary arteries and lung paren-
chyma from a single examination.27
Image acquisition. Thirty patients underwent DE-CTPA, which
used a dual-source, dual-energy CT scanner (Somatom Deﬁnition
Flash; Siemens Medical Systems, Forchheim, Germany). Pulmonary
arterial opaciﬁcation was achieved by injecting 50 mL of 370-mg
I/mL iodinated contrast medium (Ultravist 370, Bayer Healthcare,
Pittsburgh), followed by 50 mL of saline, at a rate of 5–6 mL/s, with
a high-speed dual-head injection pump. Examinations were trig-
gered by a bolus-tracking technique, with contrast arrival in the
pulmonary trunk detected with a threshold of 100 Hounsﬁeld units
(HU). DE-CTPA was performed at baseline (DE-CTPApre-CACh)
and then 10–20 minutes after the CACh (DE-CTPApost-CACh).
Figure 1. Sequence of study investigations. Group A included sys-
temic sclerosis (SSc) patients who reported increased dyspnea on
exposure to cold air, group B included SSc patients without cold-air
sensitivity, and group C included healthy volunteers. After a cold-air
inhalation challenge (CACh), pulmonary blood ﬂow (PBF) mea-
surements were performed every 5–10 minutes for 30 minutes. A
minimum “rest break” of 2 hours was then enforced, before dual-
energy computed-tomography pulmonary angiography (DE-CTPA).
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Image analysis. To determine whether overall lung density
changed after cold-air inhalation, two images from each of the DE-
CTPApre-CACh and DE-CTPApost-CACh 80-kVp axial data sets were
selected for analysis (Fig. 2). The superior image was selected at the
level of the origin of the right upper lobe bronchus, and the inferior
image was the caudalmost image on which the diaphragm was not
visible and there were no motion artifacts. Images were transferred
to a postprocessing workstation (Leonardo, Siemens), and quantita-
tive lung density analysis was performed with the Pulmo CT program
(ver. 2; Siemens), which automatically segments the lung and cal-
culates pixel attenuation coefﬁcients as previously described,32 with
minimum and maximum segmentation thresholds of −200 and
−1,024 HU, respectively (Fig. 3). The MLA generated by the pro-
gram (based on the two slices) was used for evaluation.
Change in MLA (ΔMLA) was calculated by subtracting the
DE-CTPApre-CACh MLA from the DE-CTPApost-CACh MLA, pro-
viding a measure of change in global pulmonary perfusion. Post-
processing analysis of advanced image-subtraction techniques al-
lowed the calculation of the number of pixels with intensity ratios
of between 0 and 160 (ΔI ), expressed in megapixels (1 × 106 pixels),
enabling change in regional pulmonary perfusion to be assessed
(Fig. 2C). Detailed image acquisition parameters and postprocess-
ing techniques are described in the supplement, available online.
RESULTS
Baseline characteristics
Twenty-two patients with SSc (mean age: 58 ± 9 years, 17 females)
and 9 healthy volunteers (mean age: 36 ± 10 years, 4 females) partici-
Figure 2. Dual-energy postprocessing and image subtraction on a patient from group A (with a decrease in pulmonary blood ﬂow following
cold-air inhalation). Images demonstrate dual energy–derived lung iodine maps from the superior computed-tomography slices (at the level
of the origin of the right upper lobe bronchus) before (A) and 15 minutes after (B) cold challenge, with iodine color-coded orange. The
subtracted image (C) demonstrates areas of low intensity change as “cold” colors (e.g., blue, green) and areas of high intensity change as
“warm” colors (e.g., red); however, areas of high intensity change can also be seen around misregistered vessels, a recognized artifact.
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pated in the study. All SSc patients reported a history of digital RP,
and all had undergone screening echocardiogram in the previous
12 months (with a normal mean right ventricular systolic pressure of
24.1 ± 8.0 mmHg and no other echocardiographic signs of pulmo-
nary hypertension).
Group A (SSc patients with cold-air sensitivity) included 11 pa-
tients (mean age: 58 ± 9 years, 8 females) with a median SSc disease
duration of 4 years (range: 1–13 years). Six patients had limited cuta-
neous SSc (lcSSc), and 5 had diffuse cutaneous SSc (dcSSc). On CT,
5 patients had no evidence of ILD, 5 patients had radiographic ap-
pearances of nonspeciﬁc interstitial pneumonia (NSIP), and 1 pa-
tient had overlapping appearances of usual interstitial pneumonia
(UIP) and NSIP. The mean predicted FVC was 92% ± 11%. Group B
(SSc patients without cold-air sensitivity) included 11 patients (mean
age: 60 ± 8 years, 9 females) with a median disease duration of
4 years (range: 1–27 years). Seven patients had lcSSc. On CT, 5 pa-
tients had no radiographic evidence of ILD, 5 patients had NSIP, and
1 patient had UIP. The mean predicted FVC was 87% ± 10%. Base-
line demographic and clinical information is summarized in Table 1.
PBF
Median change in PBF from baseline was compared between
groups at predeﬁned time intervals, with a signiﬁcant decline in
PBF in group A after CACh (Fig. 4). There was no statistically
signiﬁcant difference in baseline PBF between groups A and B (me-
dian: 4.6 [range: 2.6–5.1] and 4.1 [3.0–7.0] L/min, respectively; P =
0.8), although PBF was higher in group C, at 6.5 (4.5–7.1) L/min.
Ten minutes after CACh, there was a decrease in PBF of 10.0%
(−52.2% to 4.0%) in group A, compared to a 2.6% increase (−7.1%
to 25.0%; P < 0.01) in group B and no change (0.0%; −9.0% to
10.0%; P < 0.01) in group C. At 20 minutes, there was a decrease in
PBF of 17.4% (−27.9% to 0.0%) in group A, compared to a 4.9%
increase (−8.6% to 20.0%; P < 0.01) in group B and a 2.2% decrease
(−10.0% to 1.5%; P < 0.01) in group C. At 30 minutes after CACh,
there was a median decrease in PBF of 8.5% (−34.4% to 2.0%) in
group A, compared to a 1.4% increase (−5.3% to 16.1%; P < 0.01)
in group B and no change (0.0%; −11.3% to 1.3%; P < 0.01) in
group C. Median change in PBF after CACh did not differ signiﬁ-
cantly between group B and C patients at any time point (Table 2),
and no patient experienced a signiﬁcant change in FEV1 (deﬁned as
a change from baseline of at least 10%) after CACh.
DE-CTPA image analysis
Preliminary analysis of DE-CTPA data in 22 study participants
revealed no correlation between change in PBF (ΔPBF) and change
in DE-CTPA parameters. Thus, DE-CTPA analysis was not per-
formed in the remaining study participants. In one case, a techni-
cal malfunction with bolus triggering resulted in suboptimal DE-
CTPA contrast enhancement, and these data were not included
in analysis; thus, 21 patients had DE-CTPA examinations suitable
for image analysis. No patient had evidence of acute or chronic
pulmonary thromboembolism. The mean ΔPBF for the 21 patients
was −3.2% ± 11.2% (median: 0%; range: −28.0% to 16.0%). When
change in regional pulmonary perfusion after CACh was assessed,
no correlation was noted between ΔI and ΔPBF (Spearman’s ρ =
−0.06; P = 0.79). No correlation was found between ΔMLA and ΔI
(Spearman’s ρ = −0.14; P = 0.55), suggesting that changes in lung
enhancement as measured by DE-CTPA postprocessing did not sim-
ply reﬂect changes in lung density. When change in global pulmo-
nary perfusion was assessed, the mean ΔMLA was −8.6 ± 30.2 HU
(median: −10.7 HU; range: −68.2 to 70.6 HU), and no correlation
Figure 3. Quantitative computed-tomography (CT) lung density
analysis on a patient from group A, using a single CT image (at
the level of the origin of the right upper lobe bronchus). The
resultant density histograms before (A) and 15 minutes after (B)
cold challenge demonstrate no signiﬁcant change in mean lung
attenuation between the 2 CT studies, despite a demonstrated re-
duction in pulmonary blood ﬂow measured during inert-gas
rebreathing. HU: Hounsﬁeld units.
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was demonstrated between ΔMLA and ΔPBF (Spearman’s ρ =
−0.04; P = 0.85). No correlations were found between ΔI and
ΔPBF, between ΔI and ΔMLA, or between ΔMLA and ΔPBF, in
the group as a whole, or between subgroups A, B, and C (tables S1,
S2, available online).
DISCUSSION
Pulmonary hypertension develops in 10%–15% of SSc patients and
warrants early detection to allow optimal treatment and follow-up.
Predicting which patients are at risk of PH is imprecise, and several
methods of stratifying at-risk patients have been proposed, includ-
ing autoantibody proﬁle and SSc phenotype.1 While repetitive pul-
monary vasospasm is one plausible pathophysiologic mechanism
that may contribute to PH in SSc, this hypothesis remains contro-
versial, and lability of the pulmonary vasculature has proven difﬁcult
to demonstrate conclusively. At our institution, a national ILD refer-
ral center with a large SSc cohort, we have identiﬁed a subgroup of
patients who describe a clear temporal relationship between worsen-
ing respiratory symptoms (including dyspnea) and exposure to cold.
Utilizing IGR, we were able to identify a clear reduction in PBF in
a predeﬁned subgroup of SSc patients following a CACh, suggesting
that pulmonary vasospasm may be the physiologic explanation for
these symptoms.
Previous efforts to identify pulmonary vasospasm have yielded
inconsistent ﬁndings. Following cold-pressor testing in patients
with RP, several authors14-16 have reported a reduction in DLCO,
which could be explained by reduced pulmonary capillary blood
volume resulting from pulmonary vasospasm. Lampert17 reported a
reduction in DLCO in similar patients, although this was associated
with a reduction in mean pulmonary artery pressure (mPAP) and
pulmonary vascular resistance (PVR) at RHC, suggesting that vaso-
dilatation and intrapulmonary blood redistribution may be the un-
Table 1. Baseline clinical and demographic information
Group A (n = 11) Group B (n = 11) Group C (n = 9)
Age, years, mean ± SD 56.1 ± 9.0 60.3 ± 8.1 36.5 ± 10.2
lcSSc, n 6 7 NA
dcSSc, n 5 5 NA
Disease duration, years (range) 4.1 (1–13) 4.4 (1–27) NA
Echocardiogram RVSP, mmHg 26.3 ± 5.6 21.0 ± 6.4 NA
ILD pattern, n
No ILD 5 5 9
NSIP 5 5 . . .
Other 1a 1b . . .
FEV1, % predicted 79 82 104
FVC, % predicted 92 87 106
Baseline PBF, L/min (range) 4.6 (2.6–5.1) 4.1 (3.0–7.0) 6.5 (4.5–7.1)
Note: The groups were well matched, other than the younger age and higher baseline PBF in
the healthy volunteers (group C). dcSSc: diffuse cutaneous systemic sclerosis; FEV1: forced expira-
tory volume in 1 second; FVC: forced vital capacity; ILD: interstitial lung disease; lcSSc: limited
cutaneous systemic sclerosis; NSIP: nonspeciﬁc interstitial pneumonia; PBF: pulmonary blood ﬂow;
RVSP: right ventricular systolic pressure; UIP: usual interstitial pneumonia.
a UIP/NSIP overlap.
b UIP.
Figure 4. Median percentage change in pulmonary blood ﬂow
from baseline after cold-air inhalation challenge. In group A (sys-
temic sclerosis [SSc] patients with cold sensitivity), compared to
group B (SSc patients without cold sensitivity) and group C (healthy
volunteers), there was a median change in PBF of −10.0% (range:
−52.2% to 4.0%) versus +2.6% (−7.1% to 25.0%) versus 0.0% (−9.0%
to 10.0%) at 10 minutes, −17.4% (−27.9% to 0.0%) versus +4.9%
(−8.6% to 20.0%) versus −2.2% (−10.0% to 1.5%) at 20 minutes, and
−8.5% (−34.4% to 2.0%) versus +1.4% (−5.3% to 16.1%) versus 0.0%
(−11.3% to 1.3%) at 30 minutes.
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derlying pathophysiological process. Conversely, neither Miller18
nor Wise13 detected change in DLCO in SSc patients after prov-
ocation testing. Other measurement techniques, including kryp-
ton perfusion lung scan (demonstrating reduced pulmonary perfu-
sion)20 and RHC (demonstrating an increase in mPAP and PVR in
a subgroup of patients),21 have provided support for the notion of
pulmonary vasospasm, in at least a subgroup of patients. More
recently, in SSc patients with established pulmonary hypertension,
Coghlan and colleagues22 found no change in right heart catheter
parameters or circulating markers of endothelial cell activation af-
ter cold-pressor testing.
These conﬂicting results have created understandable confusion,
and a major limitation in identifying pulmonary vasospasm re-
mains the lack of a readily available, validated measure of PBF.
DLCO, used as a surrogate for PBF, depends on the area and thick-
ness of the blood-gas barrier (as described by Fick’s law of diffu-
sion) and the volume of blood within the pulmonary capillaries. A
reduction in pulmonary capillary blood volume results in a reduc-
tion in DLCO.33 However, the use of DLCO for the detection of
pulmonary vasospasm has yielded inconsistent ﬁndings, with con-
founders such as increased cardiac output, regional pulmonary va-
sodilatation, and shift in intrapulmonary blood distribution creat-
ing measurement difﬁculties.
The myocardium,2-5 brain,6-9 and kidneys10 have all been shown
to experience cold-induced vasospasm in at least a subgroup of SSc
patients. LeRoy and colleagues10 demonstrated a reduction in renal
perfusion after cold water hand immersion, while Long2 and Alexan-
der3 reported cold-induced reversible myocardial perfusion abnor-
malities during thallium scintigraphy. The presence of “cardiac RP”
has been reported to be a strong independent predictor of subse-
quent left ventricular dysfunction in SSc patients.4 Interestingly, one
patient in our cohort (who experienced a 20% reduction in PBF after
cold-air inhalation) had received a diagnosis of cardiac syndrome X
(recurrent episodes of ischemic chest pain with normal coronary
arteries at angiography) several years previously.
Our study is unique is several aspects, including the use of
noninvasive measurement techniques allowing the assessment of
both regional and global change in pulmonary perfusion. PBF mea-
surement with IGR has been validated against RHC and cardiac
MRI23,24 and has been shown to detect treatment response after
initiation of vasodilator therapy in pulmonary hypertension.34 DE-
CTPA perfusion has demonstrated good correlation with CT-
derived PBF in porcine models,35 and in our study postprocessing
techniques were employed to assess for change in both regional and
global pulmonary perfusion. We sought to improve pretest proba-
bility by identifying a subgroup of SSc patients with symptoms
(worsening dyspnea after cold exposure) plausibly explained by
pulmonary vasospasm. After an inhalational CACh as the provok-
ing stimulus (selected to mimic the physiological trigger reported
by our patients), we detected a signiﬁcant and sustained decline in
PBF in a subgroup of SSc patients, in clear contrast to healthy
volunteers and SSc patients without cold-air sensitivity (in whom
PBF did not change). Importantly, FEV1 did not change after cold-
air inhalation, suggesting that cold-induced bronchospasm was not
the explanation for worsening dyspnea in our patients.
Utilizing DE-CTPA, we were not able to demonstrate a signiﬁ-
cant correlation between the changes in MLA and those in PBF,
which may be expected with reduced pulmonary capillary blood
volume secondary to pulmonary vasospasm. It is possible that the
changes in lung perfusion are at the microscopic level and thus too
subtle to be reﬂected in changes of MLA. The lack of a correlation
between DE-CTPA-derived intensity changes and MLA changes
suggests that subtle changes in perfusion do not contribute to mea-
surable changes in lung density in a predictable manner. While pre-
vious studies in emphysema subjects have demonstrated moderate
correlations between MLA and DE-CTPA-derived perfusion,36-38
these correlations have been observed in regions of increasing
emphysema severity. It is also possible that differing postures
adopted with each measurement technique (IGR was performed in
the seated upright position, while DE-CTPA was performed su-
pine) may have resulted in changes in pulmonary perfusion and
ventilation, hampering direct comparison of the two techniques.
This study has a number of important limitations. Signiﬁcantly,
there is no accepted gold-standard measure of pulmonary vasospasm
against which to validate novel measurements techniques. While we
evaluated techniques that may identify both physiologic and radio-
Table 2. Change in PBF and FEV1 after CACh, compared to baseline measurements
Group A (n = 11) Group B (n = 11) Group C (n = 9)
Change in PBF, %
10 minutes after CACh −10.0 (−52.2 to 4.0)* +2.6 (−7.1 to 25.0) 0.0 (−9.0 to 10.0)
20 minutes after CACh −17.4 (−27.9 to 0.0)* +4.9 (−8.6 to 20.0) −2.2 (−10.0 to 1.5)
30 minutes after CACh −8.5 (−34.4 to 2.0)* +1.4 (−5.3 to 16.1) 0.0 (−11.3 to 1.3)
Change in FEV1, % −1.9 (−9.6 to 1.4%) +1.2 (−4.1 to 2.7%) −5.6 (−6.6 to 2.1%)
Note: Data are median (range). In group A patients, there was a statistically signiﬁcant change in PBF
from baseline at 10, 20, and 30 minutes after CACh. PBF did not change signiﬁcantly in group B or C
patients. There was no statistically or clinically signiﬁcant change in FEV1 in any group after CACh.
CACh: cold-air challenge; FEV1: forced expiratory volume in 1 second; PBF: pulmonary blood ﬂow.
* P < 0.01, Wilcoxon sign-rank test.
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logic changes in pulmonary perfusion (at both regional and global
perfusion levels), the lack of a gold-standard comparator does not
allow us to reach deﬁnitive conclusions from our data. Furthermore,
the optimal stimulus with which to provoke pulmonary vasospasm is
not known. Cold-air inhalation was chosen as the provoking stimu-
lus in our study, as this most closely resembled the trigger described
by our patients.
We sought to limit confounders (particularly airﬂow obstruc-
tion or ILD) that may impair interpretation of DE-CTPA and IGR
ﬁndings by recruiting only patients with limited ILD on high-
resolution CT and well-preserved spirometry. While it is possible
that cold-air inhalation may have resulted in unexpected physio-
logic consequences (such as bronchoconstriction, which was not
detectable as a change in FEV1) that may affect gas mixing and
IGR measurements, we think that this is unlikely.
A further potential confounder is the use of hypercapneic gas mix-
ture (5% CO2) and its possible effect on pulmonary vascular tone.
The net effect of CO2 on pulmonary vascular tone is dependent on
coexistent hypoxia and pH, and, analogous to the CO2 rebreathing
protocol we performed, Fishman39 reported no change in right heart
catheter hemodynamics in healthy human controls after they had
breathed a 5% CO2 mixture for 20 minutes under normoxic condi-
tions. As all participants in our study underwent an identical cold-air
inhalation protocol, any effect of hypercapneic gas inhalation on pul-
monary vascular tone should be consistent across all groups.
Conclusion. Pulmonary vasospasm may explain worsening re-
spiratory symptoms in a subgroup of SSc patients on exposure to
cold. While we identiﬁed a reduction in PBF using IGR tech-
niques, the utilization of novel measurement techniques and the
lack of a gold-standard comparator do not allow us to draw a ﬁrm
conclusion proving (or disproving) our hypothesis. Furthermore,
whether pulmonary vasospasm represents a precursor to eventual
ﬁxed pulmonary hypertension in a subgroup of SSc patients is an
intriguing hypothesis and warrants further evaluation in a larger
cohort followed longitudinally over time.
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Biomedical Research Unit at Royal Brompton and Hareﬁeld Na-
tional Health Service Foundation Trust.
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